Full Press Release Details
Transactions with shares and linked securities in Genmab A S made by managerial employees and their closely associated persons
Company Announcement
COPENHAGEN, Denmark November 19, 2025 - Genmab A S (Nasdaq GMAB) - In accordance with Article 19 of Regulation No. 596 2014 on Market Abuse and Implementing Regulation 2016 523, this document discloses the data of the transactions made in Genmab A S (Nasdaq GMAB) by managerial employees and their closely associated persons.
The company's managerial employees and their closely associated persons have given Genmab A S power of attorney on their behalf to publish trading in Genmab shares by the company's managerial employees and their closely associated persons.
Please find below a statement of such trading in shares issued by Genmab A S
| 1. | Details of the person discharging managerial responsibilities person closely associated | ||
| a) | Name | Martin Schultz | |
| 2. | Reason for the notification | ||
| a) | Position status | Member of the Board of Directors | |
| b) | Initial notification Amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Genmab A S | |
| b) | LEI-code | 529900MTJPDPE4MHJ122 | |
| 4. | Details of the transaction(s) section to be repeated for (i) each type of instrument (ii) each type of transaction (iii) each date and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Share DK0010272202 | |
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| DKK 1,960.50 | 42 | ||
| DKK 1,960.50 | 23 | ||
| DKK 1,960.50 | 28 | ||
| DKK 1,960.50 | 24 | ||
| DKK 1,960.50 | 4 | ||
| DKK 1,960.50 | 1 | ||
| DKK 1,960.00 | 20 | ||
| DKK 1,960.00 | 22 | ||
| DKK 1,960.00 | 11 |
Transactions with shares and linked securities in Genmab A S made by managerial employees and their closely associated persons
| d) | Aggregated information - Aggregated volume - Price | 175 shares DKK 1,960.35 |
| e) | Date of the transaction | 2025-11-19 |
| f) | Place of the transaction | Aquis Exchange (AQEU) CBOE Europe (CEUX) Boerse Berlin (EQTB) NASDAQ Copenhagen (XCSE) |
Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines .
Marisol Peron, Senior Vice President, Global Communications Corporate Affairs
T +1 609 524 0065 E mmp genmab.com
Andrew Carlsen, Vice President, Head of Investor Relations
T +45 3377 9558 E acn genmab.com
The Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in the Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.
Genmab A S and or its subsidiaries own the following trademarks Genmab the Y-shaped Genmab logo Genmab in combination with the Y-shaped Genmab logo HuMax DuoBody HexaBody DuoHexaBody , HexElect and KYSO .